Novifit® (NOVISAMe®) Tablets
Novifit® (NOVISAMe®) Tablets help support cognitive function of aging dogs and cats. Novifit Tablets are a highly pure and stable form of SAMe (NoviSAMe) presented in an enteric-coated tablet. As a nutraceutical, it is a first line treatment of behavioral problems associated with cognitive decline.
Novifit helps control behavioral disorders related to brain aging such as disorientation, changes in social interactions with people and other pets, changes in sleep-wake cycle and loss of housetraining skills.
Benefit:
Novifit is recommended for aging dogs and cats to help improve their level of activity and awareness.
Novifit helps to:
- Increase alertness and vitality
- Improve relationship with owner
- Regulate the sleep cycle
- Reduce housesoiling
- Delay the consequences of aging
Active Ingredients:
S-Adenosyl-L-Methionine-Tosylate Disulfate
Use:
Novifit is available from your veterinarian in packages of 30 tablets for dogs and cats weighing less than 22lbs, medium dogs weighing between 22.1 and 44lbs, and for large dogs weighing 44.1lbs or more.
The tablets can be given once a day in food, but should not be crushed or divided up into smaller pieces.
Available Sizes:
| Description | Product # |
|---|---|
| Novifit S - For Dogs and Cats 0 to 22lbs. | 42130 |
| Novifit M - For Dogs 22.1 to 44lbs. | 42230 |
| Novifit L - For Dogs 44.1 to 88lbs. | 42430 |
Resources:
Novifit® Information Detailer ( 271k - PDF File )
Novifit® - Information Detailer ( 271k - PDF File )
Novifit® Client Brochure ( PDF File - 1.19 MB )
Novifit® First Intention Guide ( PDF File - 494KB )
Appropriate use of Novifit. Written for veterinarians.
A Roundtable Discussion: S-adenosylmethionine (SAMe) and Cognitive Dysfunction in Dogs ( PDF File - 232KB )
Moderated by Gary Landsberg, BSc, DVM, DACVB
Novifit® Technical File ( PDF File - 1.42MB )
Technical profile written for veterinarians.
Clinical Relevance Study ( PDF File - 191KB )
Effect of S-Adenosylmethionine Tablets on the Reduction of Age-Related Mental Decline in Dogs: A Double-Blinded, Placebo-Controlled Trial


